Usana continues torrid pace as Q2 sales rise 30%

Nutrition & Life

Usana filed its earnings statement yesterday showing the Salt Lake City-based multilevel marketing company brought in $336.8 million, which represented a 30.1% increase over the same period a year previously.  

As usual, China leads the way

As in previous quarters, Usana sold most of its dietary supplements, functional foods and personal care items in the Asia Pacific region.  The company brought in $279 million in revenue from teh entire region, which represented a gain of 23% on a constant currency basis.

As has been true for some time, ‘Greater China’ is by far the company’s biggest market.  Usana sold $165.4 million worth of products in the company in the second quarter.  But while China is biggest, the North Asia region (primarily South Korea) was the fastest growing.  The company recorded $37.4 million in revenue in the region, representing a 33.6% rise year over year on a constant currency basis.

A few years ago the fortunes of MLMs selling nutritional products seemed to be waning in North America and Europe.  Usana, Herbalife and Nature’s Sunshine all recorded declining sales and fewer independent distributors, especially in the United States.

But those days seem to be over, as Usana notched another sales gain in the region, albeit at  a slower pace than was seen in the Asian markets. The company reported $57.9 million in sales in the region, which represented a 9.2% rise on a constant currency basis.

Online enhancements boost results

Usana CEO Christopher Guest said the company’s successful launch of its Active Nutrition line of products helped contribute to the sales success.  In addition, enhancements the company has made to streamline the online ordering process has boosted results.

Products You May Like

Articles You May Like

Semana de la Concientización de Malnutrición (MAW) – Steakers
Goodbye Pfizer, hello Comirnaty: Top COVID-19 vaccines given brand names in Canada
New treatments for COVID-19 may stave off the worst effects of the virus
Touchlight extends funding round, sees hike in demand for synthetic DNA vectors
Nuevas tecnologías para desarrollar medicamentos cada vez más rápido
FDA panel rejects plan to offer Pfizer booster shots to most Americans

Leave a Reply

Your email address will not be published. Required fields are marked *